| Revenue growth | Revenue de-grew 5% YoY; branded business up 8%. |
|---|---|
| Margins | Adjusted EBITDA margin improved 2% to 27% post-reset. |
| Demand visibility | Strong domestic branded demand; international visibility clouded by logistics. |
| Management confidence | Confident but cautious due to ongoing integration and reset phase. |
Growth
Revenue fell 5% to ₹904cr due to trade generic discontinuation; however, branded India business grew 8%.
Outlook
Management expects mid-teen growth to resume in India within 2-3 quarters; international recovery by Q2.
Risks
West Asia shipping disruptions and near-term revenue leakage from the trade generics exit remain key concerns.
Earnings Call filed with NSE, NSE: JBCHEPHARM. Summary written with AI assistance from the document.
More from J B Chemicals & Pharmaceuticals Ltd
All →J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 marked an operational reset following Torrent Pharma's acquisition of a controlling stake. Management focused on integration, distribution optimization, and rationalizing low-margin trade generics.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 shows operational reset post Torrent Pharma acquisition; revenue at ₹904cr (down 5% YoY) with adjusted EBITDA margin improving to 27%.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
JB Pharma underwent an operational reset in Q4 FY26 following the Torrent Pharma acquisition. Revenue dipped 5% to ₹904cr due to the discontinuation of low-margin trade generics and distribution realignment.
JB Chemicals & Pharmaceuticals Q4 FY26 Results: Net Profit ₹101.4 Cr, Down 30.4% YoY
JB Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹904.2 Cr (-4.8% YoY) and net profit of ₹101.4 Cr (-30.4% YoY) for Q4 FY26.
- Key figure
- Net profit ₹101.4 Cr · -30.4% YoY